摘要
戊型肝炎病毒是散发性和流行性病毒性肝炎的重要病原之一。中国一般人群中约1/3人曾感染过该病毒,主要侵犯中老年人群。虽然戊型肝炎为自限性疾病,一般不发展成慢性肝炎,但其病死率相对较高。戊型肝炎病毒至少有4个基因型,中国流行的是基因1型和4型,基因3型和4型主要见于猪,为人畜共患性疾病。中国自主研制的重组戊型肝炎疫苗(HEV239)随机双盲安慰剂对照Ⅲ期临床试验结果表明,该疫苗在我国普通人群中可有效预防戊型肝炎,且耐受性良好,有望用于高危人群的预防。
Summary ： Hepatitis E virus is a major cause of sporadic and epidemic viral hepatitis. About one third of the general population in China have been infected with the virus. The disease mainly affects lead to the middle-aged and elderly populations. Although hepatitis E tends to be self-limited and usually does not chronic hepatitis, the mortality of the disease is relatively high. At least four genotypes of hepatitis E viruses have been identified by now. Genotype 1 and 4 are prevalent in China. Genotype 3 and 4 are mainly found in pigs and are zoonotic. A ran- domized, double-blinded,placebo controlled, phase 3 trial of a recombinant vaccine, HEV 239, produced in China showed that the vaccine is well tolerated and effective in preventing hepatitis E in the general population. It might be used for prevention of hepatitis E in hi,h-risk populations.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2011年第2期81-82,共2页
Chinese Journal of Practical Internal Medicine
基金
国家"863"高技术研究发展计划资助项目(2006AA02Z453)
国家自然科学基金资助项目(30570063)
